T-PLL
MCID: TCL005
MIFTS: 49

T-Cell Prolymphocytic Leukemia (T-PLL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for T-Cell Prolymphocytic Leukemia

MalaCards integrated aliases for T-Cell Prolymphocytic Leukemia:

Name: T-Cell Prolymphocytic Leukemia 52 58 29 6 17 71
T-Cell Chronic Lymphocytic Leukemia 58
Lymphocytic Leukemia T-Cell Chronic 54
T Cell Prolymphocytic Leukemia 52
Leukemia, T-Cell, Chronic 71
T-Pll 58

Characteristics:

Orphanet epidemiological data:

58
t-cell prolymphocytic leukemia
Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

ICD10 32 C91.6
MESH via Orphanet 44 D015461
ICD10 via Orphanet 33 C91.6
UMLS via Orphanet 72 C0023494 C2363142
Orphanet 58 ORPHA86871
UMLS 71 C0023494 C2363142

Summaries for T-Cell Prolymphocytic Leukemia

MalaCards based summary : T-Cell Prolymphocytic Leukemia, also known as t-cell chronic lymphocytic leukemia, is related to telangiectasis and ataxia-telangiectasia. An important gene associated with T-Cell Prolymphocytic Leukemia is ATM (ATM Serine/Threonine Kinase), and among its related pathways/superpathways are ERK Signaling and Human cytomegalovirus infection. The drugs Mitoxantrone and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone marrow and bone, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 T-cell-prolymphocytic leukemia (T-PLL) is a mature T-cell leukemia with aggressive behavior and... more...

Related Diseases for T-Cell Prolymphocytic Leukemia

Diseases in the B Cell Prolymphocytic Leukemia family:

T-Cell Prolymphocytic Leukemia

Diseases related to T-Cell Prolymphocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 153)
# Related Disease Score Top Affiliating Genes
1 telangiectasis 30.7 VEGFA CHEK2 ATM
2 ataxia-telangiectasia 30.7 TCL1A MTCP1 CHEK2 ATM ABL1
3 prolymphocytic leukemia 30.7 TCL1A MYC MTCP1 JAK3 JAK1 HLA-S
4 t-cell lymphoblastic leukemia/lymphoma 30.5 TCL1A NFKB1 MYC MTCP1 CD7
5 b cell prolymphocytic leukemia 30.5 MYC MS4A1
6 leukemia 30.3 TCL1A MYC MTCP1 JAK3 JAK1 CHEK2
7 adult t-cell leukemia 30.3 MYC JAK3 CD7
8 b-cell lymphoma 30.1 TCL1A MYC MS4A1 CDKN1B ATM
9 precursor t-cell acute lymphoblastic leukemia 30.0 TCL1A MYC CD7 ABL1
10 sezary's disease 30.0 MYC JAK3 CD7 CD52
11 nijmegen breakage syndrome 29.9 MYC CHEK2 ATM
12 lymphoma 29.9 TCL1A MYC MS4A1 CHEK2 CDKN1B ATM
13 leukemia, chronic lymphocytic 29.3 VEGFA TCL1A MYC MS4A1 CD7 CD52
14 leukemia, acute lymphoblastic 29.3 MYC JAK3 JAK1 CDKN1B CD7 ATM
15 leukemia, acute myeloid 28.1 VEGFA MYC JAK3 JAK1 CHEK2 CDKN1B
16 leukemia, t-cell, chronic 10.8
17 splenomegaly 10.7
18 chromosomal triplication 10.6
19 lymphoproliferative syndrome 10.5
20 ataxia and polyneuropathy, adult-onset 10.5
21 diffuse large b-cell lymphoma 10.5
22 thrombocytopenia 10.5
23 t-cell lymphoma 1a 10.5
24 chromosome 8q duplication 10.4
25 kaposi sarcoma 10.4
26 exanthem 10.4
27 purpura 10.4
28 bile duct cystadenoma 10.3 CHEK2 ATM
29 maxillary sinus adenocarcinoma 10.3 CDKN1B ATM
30 jak3-deficient severe combined immunodeficiency 10.3 JAK3 JAK1
31 lymphoma aids related 10.3 TCL1A MYC
32 peripheral t-cell lymphoma 10.3
33 t-cell large granular lymphocyte leukemia 10.3
34 hemolytic anemia 10.3
35 pityriasis lichenoides 10.2 MS4A1 CD7
36 leukemia, chronic lymphocytic 2 10.2 MS4A1 ATM
37 t-cell adult acute lymphocytic leukemia 10.2 JAK3 CD7 CD52
38 lymphoblastic leukemia, acute, with lymphomatous features 10.2 JAK3 JAK1 ABL1
39 b-cell growth factor 10.1
40 pure red-cell aplasia 10.1
41 agammaglobulinemia 10.1
42 red cell aplasia 10.1
43 breast cancer 10.1
44 lymphoma, mucosa-associated lymphoid type 10.1
45 retinal detachment 10.1
46 thrombophilia due to thrombin defect 10.1
47 anemia, autoimmune hemolytic 10.1
48 factor v deficiency 10.1
49 mycosis fungoides 10.1
50 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.1

Graphical network of the top 20 diseases related to T-Cell Prolymphocytic Leukemia:



Diseases related to T-Cell Prolymphocytic Leukemia

Symptoms & Phenotypes for T-Cell Prolymphocytic Leukemia

GenomeRNAi Phenotypes related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

26 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 10.02 ABL1 MYC SMARCB1
2 Decreased viability GR00221-A-2 10.02 ABL1 CHEK2 SMARCB1
3 Decreased viability GR00221-A-3 10.02 ABL1 ATM CHEK2 JAK3 MYC SMARCB1
4 Decreased viability GR00221-A-4 10.02 ATM CHEK2
5 Decreased viability GR00249-S 10.02 MYC SMARCB1
6 Decreased viability GR00342-S-1 10.02 ABL1
7 Decreased viability GR00342-S-2 10.02 ABL1 CHEK2
8 Decreased viability GR00342-S-3 10.02 ABL1
9 Decreased viability GR00381-A-1 10.02 SMARCB1
10 Decreased viability GR00402-S-2 10.02 JAK3 MYC
11 Decreased Hepatitis C Virus pseudoparticles (HCVpp; H77; genotype 1a) infection GR00234-A-1 9.43 ATM CDKN1B JAK1
12 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.33 ATM CHEK2 JAK3
13 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.28 NFKB1
14 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.28 ABL1 ATM NFKB1
15 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.28 ATM C11orf65 CDKN1B CHEK2 NFKB1

MGI Mouse Phenotypes related to T-Cell Prolymphocytic Leukemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.07 ABL1 ATM CD7 CDKN1B CHEK2 JAK1
2 endocrine/exocrine gland MP:0005379 10.02 ABL1 ATM CD7 CDKN1B CHEK2 JAK1
3 immune system MP:0005387 10 ABL1 ATM CD7 CDKN1B CHEK2 JAK1
4 liver/biliary system MP:0005370 9.5 ABL1 CDKN1B JAK1 MYC NFKB1 SMARCB1
5 neoplasm MP:0002006 9.17 ATM CDKN1B CHEK2 KLRB1 MYC SMARCB1

Drugs & Therapeutics for T-Cell Prolymphocytic Leukemia

Drugs for T-Cell Prolymphocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 31)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mitoxantrone Approved, Investigational Phase 2 65271-80-9 4212
2
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
3
Venetoclax Approved, Investigational Phase 2 1257044-40-8 49846579
4
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
5
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
6 Analgesics Phase 2
7 Antirheumatic Agents Phase 2
8 Antimetabolites Phase 2
9
Niraparib Approved, Investigational Phase 1 1038915-60-4 24958200
10
alemtuzumab Approved, Investigational Phase 1 216503-57-0
11
Fludarabine Approved Phase 1 21679-14-1, 75607-67-9 30751
12
Vidarabine Approved, Investigational Phase 1 24356-66-9 21704 32326
13
Romidepsin Approved, Investigational Phase 1 128517-07-7 5352062
14
Busulfan Approved, Investigational Phase 1 55-98-1 2478
15
Sirolimus Approved, Investigational Phase 1 53123-88-9 5284616 6436030 46835353
16 Poly(ADP-ribose) Polymerase Inhibitors Phase 1
17 Immunoglobulins Phase 1
18 Antibodies Phase 1
19 Immunoglobulins, Intravenous Phase 1
20 Antibodies, Monoclonal Phase 1
21 Immunologic Factors Phase 1
22 Antineoplastic Agents, Immunological Phase 1
23 Immunosuppressive Agents Phase 1
24 Alkylating Agents Phase 1
25 Anti-Infective Agents Phase 1
26 Antiviral Agents Phase 1
27 Anti-Bacterial Agents Phase 1
28 Thymoglobulin Phase 1
29 Antibiotics, Antitubercular Phase 1
30 Antilymphocyte Serum Phase 1
31 Hormones Phase 1

Interventional clinical trials:

(show all 15)
# Name Status NCT ID Phase Drugs
1 Consolidation With Campath-1H After FMC Induction in Patients With T-cell Chronic Lymphocytic Leukemia Completed NCT00278213 Phase 2 cyclophosphamide;fludarabine phosphate;mitoxantrone hydrochloride
2 Phase II Trial of Combined Immunochemotherapy With Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab (FMC-Alemtuzumab) in Patients With Previously Treated or Untreated T-Prolymphocytic Leukemia Completed NCT01186640 Phase 2 Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab;Alemtuzumab
3 A Prospective, Open-Label, Single-Arm, Phase 2, Multicenter Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects With T-Cell Prolymphocytic Leukemia Recruiting NCT03873493 Phase 2 Venetoclax;Ibrutinib
4 Phase II Study of 5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia Terminated NCT00413478 Phase 2 5-Azacytidine
5 Phase II Study of Bortezomib (VELCADE) for the Treatment of Relapsed or Refractory T-cell Prolymphocytic Leukemia Withdrawn NCT01162031 Phase 2 Velcade
6 A Phase I Study of MK-4827 in Patients With Advanced Solid Tumors or Hematologic Malignancies Completed NCT00749502 Phase 1 MK-4827
7 A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of GRN163L in Patients With Chronic Lymphoproliferative Disease Completed NCT00124189 Phase 1 GRN163L
8 A Pharmacokinetic and Pharmacodynamic Study to Evaluate the Safety and Feasibility of Continuous Infusion Nelarabine in Patients With Relapsed / Refractory Lymphoid Malignancies Completed NCT01094860 Phase 1 Nelarabine
9 Phase Ib Pilot Study of Itacitinib With Alemtuzumab in Patients With T-Cell Prolymphocytic Leukemia (T-PLL) Recruiting NCT03989466 Phase 1 Itacitinib
10 A Phase 1 Trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies Recruiting NCT02576496 Phase 1 Tinostamustine
11 A Phase I Study Of Subcutaneous Recombinant Human IL-15 (S.C.rhIL-15) and Alemtuzumab for Patients With Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL) Recruiting NCT02689453 Phase 1
12 Romidepsin Therapy in Conditioning and Maintenance in Patients With T-Cell Malignancies Receiving Allogeneic Stem Cell Transplant Recruiting NCT02512497 Phase 1 Romidepsin;Busulfan;Fludarabine;Thymoglobulin
13 A Phase 1a/1b, Multicenter, Open Label, Dosefinding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual Dna-pk and Tor Kinase Inhibitor, Cc-115, Administered Orally to Subjects With Advanced Solid Tumors and Hematologic Malignancies Active, not recruiting NCT01353625 Phase 1 CC-115
14 Registry of the German CLL Study Group Long Term Follow-up of Patients With CLL, B-PLL, T-PLL, SLL,T or NK-LGL, HCL and Richter's Transformation Recruiting NCT02863692
15 Prospective and Retrospective Study Evaluating Epidemiological, Clinical, Molecular and Therapeutic Data of Prolymphocytic Leukemia T Not yet recruiting NCT04411043

Search NIH Clinical Center for T-Cell Prolymphocytic Leukemia

Genetic Tests for T-Cell Prolymphocytic Leukemia

Genetic tests related to T-Cell Prolymphocytic Leukemia:

# Genetic test Affiliating Genes
1 T-Cell Prolymphocytic Leukemia 29

Anatomical Context for T-Cell Prolymphocytic Leukemia

MalaCards organs/tissues related to T-Cell Prolymphocytic Leukemia:

40
T Cells, Bone Marrow, Bone, Skin, Spleen, Liver, Lymph Node

Publications for T-Cell Prolymphocytic Leukemia

Articles related to T-Cell Prolymphocytic Leukemia:

(show top 50) (show all 444)
# Title Authors PMID Year
1
Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. 61 6
9334731 1997
2
Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. 6 61
9288106 1997
3
Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry. 6
16958054 2006
4
Mice heterozygous for mutation in Atm, the gene involved in ataxia-telangiectasia, have heightened susceptibility to cancer. 6
12195425 2002
5
ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. 6
9463314 1998
6
A high frequency of distinct ATM gene mutations in ataxia-telangiectasia. 6
8808599 1996
7
ATM mutations in cancer families. 6
8797579 1996
8
Mutations associated with variant phenotypes in ataxia-telangiectasia. 6
8755918 1996
9
Role of TCL1 and ALL1 in human leukemias and development. 54 61
10197596 1999
10
Epstein-Barr virus-positive diffuse large B-cell lymphoma after sustained remission of T-cell prolymphocytic leukemia with alemtuzumab. 61
31960738 2020
11
T-cell prolymphocytic leukemia: Review of an entity and its differential diagnostic considerations. 61
32543075 2020
12
Current understandings on T-cell prolymphocytic leukemia and its association with TCL1 proto-oncogene. 61
32247279 2020
13
Generalized pruritic dark papules in a patient with T-cell prolymphocytic leukemia - a clinicopathological challenge. 61
31515798 2020
14
What to Look Out for when Transplanting T-Cell Prolymphocytic Leukemia. 61
32369824 2020
15
T-Cell Prolymphocytic Leukemia: Long-Term Remissions Challenging! 61
32392564 2020
16
A Rare Association: Autoimmune Hemolytic Anemia With Indolent T-Cell Prolymphocytic Leukemia. 61
32523849 2020
17
Patterns of Late Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with T-Cell Prolymphocytic Leukemia. 61
32259827 2020
18
Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemia. 61
31677197 2020
19
Sensitizing the interdisciplinary team to desensitizations: An alemtuzumab case report. 61
31390960 2020
20
Advances and Perspectives in the Treatment of T-PLL. 61
32034661 2020
21
SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy. 61
32012154 2020
22
First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL). 61
31566032 2020
23
Dual dependence on BCL2 and MCL1 in T-cell prolymphocytic leukemia. 61
32040552 2020
24
CHORIOCAPILLARIS FLOW VOIDS IN CRYPTOCOCCAL CHOROIDITIS USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY. 61
29373342 2020
25
Direct Targeting Options for STAT3 and STAT5 in Cancer. 61
31817042 2019
26
Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia. 61
31698446 2019
27
Bilateral tonsillar infiltration of T-cell prolymphocytic leukemia. 61
31788291 2019
28
JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL. 61
31766351 2019
29
T-PLL: harmonizing criteria for research. 61
31582368 2019
30
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. 61
31292114 2019
31
EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL). 61
30664723 2019
32
Genomics of LGL leukemia and select other rare leukemia/lymphomas. 61
31585620 2019
33
Effect of allogeneic hematopoietic cell transplantation for patients with T-prolymphocytic leukemia: a retrospective study from the Adult Lymphoma Working Group of the Japan Society for hematopoietic cell transplantation. 61
31327025 2019
34
CD161 Is Expressed in a Subset of T-Cell Prolymphocytic Leukemia Cases and Is Useful for Disease Follow-up. 61
31305900 2019
35
B and T cell prolymphocytic leukaemia. 61
31585622 2019
36
T-cell prolymphocytic leukemia presenting with erythematous patches, plaques, and erythema gyratum-like lesions masquerading as Sézary syndrome. 61
31440557 2019
37
Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. 61
30997845 2019
38
T-cell prolymphocytic leukemia presenting as ascites. 61
31345928 2019
39
Cytoplasmic Blebs in T-Cell Prolymphocytic Leukemia. 61
31189039 2019
40
[Successful Treatment of T-Cell Prolymphocytic Leukemia with Alemtuzumab]. 61
31189814 2019
41
Where do we currently stand with T-cell prolymphocytic leukemia? 61
30668215 2019
42
New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance. 61
30234404 2019
43
Clinically silent indolent T-cell leukemia. 61
30656001 2019
44
Persistent Mixed Donor Chimerism following Double Umbilical Cord Transplantation in a Patient with T-Cell Prolymphocytic Leukemia. 61
31612087 2019
45
The dawn of a new era in treating T-PLL. 61
30774758 2019
46
Papuloerythroderma-like cutaneous involvement of a CD62L- subclone of T-cell prolymphocytic leukemia. 61
30450688 2019
47
False-Positive Light Chain Clonal Restriction by Flow Cytometry in Patients Treated With Alemtuzumab: Potential Pitfalls for the Misdiagnosis of B-Cell Neoplasms. 61
30307483 2019
48
Composite Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and T-Prolymphocytic Leukemia Presenting with Lymphocytosis, Skin Lesions, and Generalized Lymphadenopathy. 61
30941227 2019
49
Small cell variant of T-cell prolymphocytic leukemia with atypical presentation. 61
30588459 2018
50
Next-generation amplicon TRB locus sequencing can overcome limitations of flow-cytometric Vβ expression analysis and confirms clonality in all T-cell prolymphocytic leukemia cases. 61
30414304 2018

Variations for T-Cell Prolymphocytic Leukemia

ClinVar genetic disease variations for T-Cell Prolymphocytic Leukemia:

6 ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 ATM NM_000051.3(ATM):c.5044G>C (p.Asp1682His)SNV Pathogenic 3026 rs121434217 11:108170479-108170479 11:108299752-108299752
2 ATM NM_000051.3(ATM):c.5309C>G (p.Ser1770Ter)SNV Pathogenic 3042 rs121434223 11:108172506-108172506 11:108301779-108301779
3 ATM NM_001330368.2(C11orf65):c.641-22822_641-22814deldeletion Pathogenic/Likely pathogenic 3019 rs587776547 11:108202612-108202620 11:108331885-108331893
4 ATM NM_000051.3(ATM):c.7271T>G (p.Val2424Gly)SNV Pathogenic/Likely pathogenic 3023 rs28904921 11:108199929-108199929 11:108329202-108329202

Copy number variations for T-Cell Prolymphocytic Leukemia from CNVD:

7 (show top 50) (show all 758)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 14323 1 107060000 118270000 Deletion T-cell prolymphocytic leukemia
2 17205 1 141501392 142732360 Amplification T-cell prolymphocytic leukemia
3 19890 1 151880356 153088354 Deletion T-cell prolymphocytic leukemia
4 22015 1 164099958 164243756 Amplification T-cell prolymphocytic leukemia
5 24296 1 178292024 178520303 Amplification T-cell prolymphocytic leukemia
6 24451 1 180754716 183730500 Amplification T-cell prolymphocytic leukemia
7 25710 1 193462805 193618427 Deletion T-cell prolymphocytic leukemia
8 26226 1 198221297 245353397 Amplification T-cell prolymphocytic leukemia
9 29813 1 236310000 236970000 Deletion T-cell prolymphocytic leukemia
10 31149 1 25598247 25881984 Deletion T-cell prolymphocytic leukemia
11 31214 1 26102907 26624823 Deletion T-cell prolymphocytic leukemia
12 31215 1 26102907 26936965 Deletion T-cell prolymphocytic leukemia
13 31328 1 26860573 29239576 Deletion T-cell prolymphocytic leukemia
14 35233 1 6146230 6344245 Deletion T-cell prolymphocytic leukemia
15 35791 1 67452671 99313693 Deletion T-cell prolymphocytic leukemia
16 36896 1 825852 120863833 Amplification T-cell prolymphocytic leukemia
17 39073 10 108954534 111745117 Deletion T-cell prolymphocytic leukemia
18 39204 10 111824569 135311386 Amplification T-cell prolymphocytic leukemia
19 40780 10 133604797 135311386 Deletion T-cell prolymphocytic leukemia
20 41072 10 135165535 135311386 Amplification T-cell prolymphocytic leukemia
21 41217 10 148946 135311386 Amplification T-cell prolymphocytic leukemia
22 41219 10 148946 5692243 Deletion T-cell prolymphocytic leukemia
23 41413 10 17718148 22325377 Deletion T-cell prolymphocytic leukemia
24 41736 10 23032969 39064552 Deletion T-cell prolymphocytic leukemia
25 41964 10 26990000 30260000 Deletion T-cell prolymphocytic leukemia
26 42441 10 34110000 35980000 Deletion T-cell prolymphocytic leukemia
27 43355 10 46363383 47154881 Amplification T-cell prolymphocytic leukemia
28 44297 10 54778135 56318960 Deletion T-cell prolymphocytic leukemia
29 45076 10 67100000 71360000 Deletion T-cell prolymphocytic leukemia
30 46742 10 85720790 86922140 Deletion T-cell prolymphocytic leukemia
31 47214 10 90488702 94393578 Deletion T-cell prolymphocytic leukemia
32 48517 11 100045570 103051410 Deletion T-cell prolymphocytic leukemia
33 49138 11 10330000 11140000 Deletion T-cell prolymphocytic leukemia
34 49397 11 106417979 114849006 Deletion T-cell prolymphocytic leukemia
35 49494 11 107346114 107685623 Deletion T-cell prolymphocytic leukemia
36 49495 11 107346114 108015771 Deletion T-cell prolymphocytic leukemia
37 49502 11 107401046 107685623 Deletion T-cell prolymphocytic leukemia
38 49503 11 107419503 108193907 Deletion T-cell prolymphocytic leukemia
39 49515 11 107511257 108661992 Deletion T-cell prolymphocytic leukemia
40 49523 11 107598768 107745036 Deletion ATM T-cell prolymphocytic leukemia
41 49774 11 110891599 111596604 Deletion T-cell prolymphocytic leukemia
42 50371 11 117492601 119996648 Deletion T-cell prolymphocytic leukemia
43 50952 11 120493810 122186945 Deletion T-cell prolymphocytic leukemia
44 51031 11 122000000 131630000 Gain T-cell prolymphocytic leukemia
45 51124 11 123252803 123608170 Deletion T-cell prolymphocytic leukemia
46 51271 11 124529138 125115632 Deletion T-cell prolymphocytic leukemia
47 51421 11 125855565 126161131 Deletion T-cell prolymphocytic leukemia
48 51521 11 127437820 128227400 Deletion T-cell prolymphocytic leukemia
49 51526 11 127525578 128328976 Deletion T-cell prolymphocytic leukemia
50 51529 11 127550030 128131996 Deletion T-cell prolymphocytic leukemia

Expression for T-Cell Prolymphocytic Leukemia

Search GEO for disease gene expression data for T-Cell Prolymphocytic Leukemia.

Pathways for T-Cell Prolymphocytic Leukemia

Pathways related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.82 VEGFA NFKB1 MYC JAK3 JAK1 CHEK2
2
Show member pathways
12.92 VEGFA SAMHD1 NFKB1 MYC JAK1 ATM
3
Show member pathways
12.86 VEGFA NFKB1 MYC JAK1 CDKN1B ABL1
4
Show member pathways
12.81 NFKB1 MYC JAK3 JAK1 CDKN1B
5 12.78 VEGFA NFKB1 MYC JAK3 JAK1 CDKN1B
6
Show member pathways
12.77 NFKB1 MYC JAK3 JAK1 CDKN1B
7
Show member pathways
12.64 VEGFA TCL1A NFKB1 MYC MTCP1 JAK3
8
Show member pathways
12.59 VEGFA NFKB1 MYC JAK1 CDKN1B ABL1
9 12.49 CHEK2 CDKN1B BRCC3 ATM
10
Show member pathways
12.49 VEGFA NFKB1 MYC JAK1 ABL1
11 12.49 VEGFA NFKB1 MYC CDKN1B ATM ABL1
12
Show member pathways
12.39 VEGFA NFKB1 JAK3 JAK1
13
Show member pathways
12.38 NFKB1 MYC JAK3 JAK1 CDKN1B
14
Show member pathways
12.36 CHEK2 BRCC3 ATM ABL1
15
Show member pathways
12.36 MYC CHEK2 CDKN1B ATM ABL1
16 12.34 MYC CHEK2 CDKN1B ATM ABL1
17 12.29 NFKB1 JAK3 JAK1 CDKN1B
18
Show member pathways
12.27 VEGFA NFKB1 JAK3 JAK1 CDKN1B
19 12.26 NFKB1 MYC CDKN1B ATM
20
Show member pathways
12.25 SAMHD1 MYC JAK1 ATM ABL1
21
Show member pathways
12.21 NFKB1 MYC CHEK2 CDKN1B
22 12.18 VEGFA NFKB1 MYC JAK1
23 12.14 NFKB1 MYC CHEK2 ATM
24 12.14 NFKB1 MYC JAK3 JAK1 CHEK2 ATM
25 11.96 VEGFA MYC JAK3 JAK1
26 11.89 VEGFA NFKB1 CDKN1B
27
Show member pathways
11.86 NFKB1 JAK3 JAK1
28 11.85 NFKB1 MYC CDKN1B
29 11.83 MYC CDKN1B ABL1
30 11.83 NFKB1 MYC CDKN1B ATM ABL1
31
Show member pathways
11.82 CHEK2 ATM ABL1
32
Show member pathways
11.8 SMARCB1 CHEK2 ATM
33 11.73 MYC CDKN1B ATM
34 11.7 MYC JAK1 CDKN1B
35 11.68 MYC CHEK2 ATM
36
Show member pathways
11.66 NFKB1 MYC JAK3 JAK1
37 11.63 CHEK2 ATM ABL1
38
Show member pathways
11.61 NFKB1 MYC JAK1 CDKN1B
39 11.6 SMARCB1 CDKN1B ABL1
41 11.51 NFKB1 MYC JAK1
42 11.5 VEGFA NFKB1 MYC JAK1
43 11.49 NFKB1 CHEK2 ATM
44 11.48 MYC CDKN1B ATM ABL1
45 11.47 NFKB1 MYC CDKN1B ATM ABL1
46
Show member pathways
11.44 VEGFA JAK3 JAK1
47 11.44 VEGFA NFKB1 MYC CDKN1B
48
Show member pathways
11.38 MYC JAK3 JAK1 CDKN1B
49 11.35 NFKB1 MYC JAK1
50 11.35 NFKB1 MYC CHEK2 ATM

GO Terms for T-Cell Prolymphocytic Leukemia

Cellular components related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.7 TCL1A SMARCB1 SAMHD1 NFKB1 MYC MS4A1
2 protein-containing complex GO:0032991 9.1 TCL1A SMARCB1 MYC MTCP1 CDKN1B ABL1

Biological processes related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.97 VEGFA TCL1A NFKB1 MYC CDKN1B
2 cytokine-mediated signaling pathway GO:0019221 9.89 VEGFA MYC JAK3 JAK1
3 phosphorylation GO:0016310 9.88 JAK3 JAK1 CHEK2 CDKN1B ATM ABL1
4 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.72 VEGFA TCL1A MTCP1
5 cellular response to DNA damage stimulus GO:0006974 9.63 SAMHD1 MYC CHEK2 BRCC3 ATM ABL1
6 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.61 CHEK2 CDKN1B ATM
7 positive regulation of response to DNA damage stimulus GO:2001022 9.58 MYC ATM
8 replicative senescence GO:0090399 9.57 CHEK2 ATM
9 interleukin-15-mediated signaling pathway GO:0035723 9.56 JAK3 JAK1
10 cell cycle arrest GO:0007050 9.56 MYC CDKN1B ATM ABL1
11 cellular response to angiotensin GO:1904385 9.54 NFKB1 MYC
12 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.54 CHEK2 ATM ABL1
13 signal transduction in response to DNA damage GO:0042770 9.52 CHEK2 ABL1
14 positive regulation of mitochondrial membrane potential GO:0010918 9.51 TCL1A MYC
15 ovarian follicle development GO:0001541 9.5 VEGFA MYC ATM
16 interleukin-2-mediated signaling pathway GO:0038110 9.49 JAK3 JAK1
17 interleukin-9-mediated signaling pathway GO:0038113 9.48 JAK3 JAK1
18 interleukin-21-mediated signaling pathway GO:0038114 9.46 JAK3 JAK1
19 DNA repair GO:0006281 9.43 SMARCB1 SAMHD1 CHEK2 BRCC3 ATM ABL1
20 DNA damage induced protein phosphorylation GO:0006975 8.8 CHEK2 ATM ABL1

Molecular functions related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.65 JAK3 JAK1 CHEK2 ATM ABL1
2 kinase activity GO:0016301 9.43 JAK3 JAK1 CHEK2 CDKN1B ATM ABL1
3 protein phosphatase binding GO:0019903 9.33 JAK3 JAK1 CDKN1B
4 non-membrane spanning protein tyrosine kinase activity GO:0004715 8.8 JAK3 JAK1 ABL1

Sources for T-Cell Prolymphocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....